Company news
Trivarx Limited (ASX:TRI) news
Trivarx Limited news releases on 6ix. Latest, Apr 27, 2023: March 2023 Quarterly Activities Report and Appendix 4C
Press releases — page 2
March 2023 Quarterly Activities Report and Appendix 4C
April 26, 2023
MEB Executes Bridging Loans with Directors
April 21, 2023
Share Purchase Plan Supplementary Prospectus
April 14, 2023
Share Purchase Plan Prospectus
March 1, 2023
Half Yearly Report and Accounts
February 24, 2023
MEB to Raise up to $2.75 million By Way of a Placement & SPP
February 14, 2023
Medibio Quarterly Update and Cashflow Report
January 30, 2023
Medibio Receives R&D Tax Incentive Refund
November 14, 2022
Medibio Appoints CEO
September 19, 2022
Appendix 4E and Preliminary Final Report
August 31, 2022
Sleep Analysis Depressive Burden Study Clinical Trial
July 20, 2022
MEB to Raise $1.4m by way of a Placement & MD/CEO Resigns
June 22, 2022
Reinstatement to Quotation
June 22, 2022
Voluntary Suspension
June 16, 2022
FDA Confirm Diagnostic Method on Depression Validation Trial
May 18, 2022
Medibio Announces Entitlement Offer Result
March 10, 2022
Termination of Underwriting Agreement
March 1, 2022
Non-Renounceable Entitlement Offer Underwriting Update
January 20, 2022
MEB to Raise up to $5.7 million by way of a Placement & NREO
December 14, 2021
FDA Strategy and Regulatory Update
October 25, 2021
Appendix 4E and Annual Report
August 31, 2021
MEB Appoints R&CPMK As Communications Agency in the US
June 24, 2021
Medibio strengthens its IP protection
May 3, 2021
Re-submission of FDA 510(k) application
April 28, 2021
Consumer Mental Health App Development - Second Test Phase
April 21, 2021
MEB Share Purchase Plan Closes Strongly Oversubscribed
March 31, 2021
Supplementary Prospectus
March 31, 2021
MEB Begins Implementation of ilumen In the United Kingdom
March 18, 2021
Underwritten Share Purchase Plan Update
February 15, 2021
MEB to Raise up to $3.5m By Way of a Placement and SPP
February 10, 2021
Medibio Granted CE Mark Approval for MEBsleep
January 18, 2021
Consumer Mental Health App Initial testing phase commenced
January 10, 2021
US FDA advises further data needed for MEBsleep approval
December 28, 2020
Update on Breakthrough Device Program
December 3, 2020
Global Master License & Services Agreement with Compass
November 22, 2020
AGM Presentation
November 12, 2020
MEB Signs Clinical Trial Agreement with MedBridge Healthcare
October 6, 2020
Request For FDA Breakthrough Device Designation Submitted
October 1, 2020
Patent Granted to Monitor Stress Conditions Using Heartrate
August 9, 2020
Entitlement Issue Results
July 9, 2020
Entitlement Offer Booklet
June 10, 2020
Placement and Fully Underwritten Entitlement Offer
June 9, 2020
Medibio submits FDA 510K Application to FDA
April 29, 2020
Final Compass Pilot Completed Successfully
April 8, 2020
Strategic Plan for FDA and CE Mark Approval
February 13, 2020
Company Update
December 8, 2019
Results of Annual General Meeting
November 22, 2019
Pause in Trading
November 21, 2019
Medibio Signs Agreement with PwC Australia for ilumen
October 23, 2019
MEB successfully completes first Ilumen pilot with Compass
October 20, 2019